Publication date: Jun 19, 2019
Immunohistochemistry (IHC) can be applied to diagnostic aspects of pathologic examination to provide aid in assignment of lineage and histologic type of cancer. Increasingly, however, IHC is widely used to provide prognostic and predictive (theranostic) information about the neoplastic disease. A refinement of theranostic application of IHC can be seen in the use of “genomic probing” where antibody staining results are directly correlated with an underlying genetic alteration in the tumor (somatic mutations) and/or the patient (germline constitution). All these aspects of IHC find their best use in guiding the oncologists in the optimal use of therapy for the patients.
Gatalica, Z., Feldman, R., Vrani’c, S., and Spetzler, D. Immunohistochemistry-Enabled Precision Medicine. 04927. 2019 Cancer Treat Res (178):
- Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing.